The short version of gastric juice protein fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-29. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
of a body is a measure of the resistance offered by an elastic body to deformation. For an elastic body with a single degree of freedom (DOF) (for example, stretching or compression of a rod), the stiffness is defined as
A wide variety of neptunium sulfide compounds have been characterized, including the pure sulfide compounds NpS, NpS3, Np2S5, Np3S5, Np2S3, and Np3S4. Of these, Np2S3, prepared by reacting NpO2 with hydrogen sulfide and carbon disulfide at around 1000 °C, is the most well-studied and three allotropic forms are known. The α form exists up to around 1230 °C, the β up to 1530 °C, and the γ form, which can also exist as Np3S4, at higher temperatures. NpS can be produced by reacting Np2S3 and neptunium metal at 1600 °C and Np3S5 can be prepared by the decomposition of Np2S3 at 500 °C or by reacting sulfur and neptunium hydride at 650 °C. Np2S5 is made by heating a mixture of Np3S5 and pure sulfur to 500 °C. All of the neptunium sulfides except for the β and γ forms of Np2S3 are isostructural with the equivalent uranium sulfide and several, including NpS, α−Np2S3, and β−Np2S3 are also isostructural with the equivalent plutonium sulfide. The oxysulfides NpOS, Np4O4S3, and Np2O2S have also been produced, although the latter two have not been well studied. NpOS was first prepared in 1985 by vacuum sealing NpO2, Np3S5, and pure sulfur in a quartz tube and heating it to 900 °C for one week. Neptunium selenide compounds that have been reported include NpSe, NpSe3, Np2Se3, Np2Se5, Np3Se4, and Np3Se5. All of these have only been obtained by heating neptunium hydride and selenium metal to various temperatures in a vacuum for an extended period of time and Np2Se3 is only known to exist in the γ allotrope at relatively high temperatures.
==== Gallic acid biosynthesis ==== Gallic acid is formed from 3-dehydroshikimate by the action of the enzyme shikimate dehydrogenase to produce 3,5-didehydroshikimate. This latter compound spontaneously rearranges to gallic acid.
==== Kino-Pravda ==== Dziga Vertov was central to the Soviet Kino-Pravda (literally, "cinematic truth") newsreel series of the 1920s. Vertov believed the camera – with its varied lenses, shot-counter shot editing, time-lapse, ability to slow motion, stop motion and fast-motion – could render reality more accurately than the human eye, and created a film philosophy from it.
Sources: en.wikipedia.org
The series begins with a streamer (WayneRadioTV) playing a mod of Half-Life with VR support and intelligent AI characters. He begins a Let's Play, roleplaying as Gordon Freeman. Freeman is walking through the Black Mesa Research Facility and encounters Benry (Socpens), an antagonistic security guard who demands he provide a passport for identification, and begins to follow and taunt him. Freeman also comes across three eccentric scientists: Tommy Coolatta (Baaulp), who is childlike and book smart, Dr. Harold Coomer (Hollow_tones), who is friendly and the subject of frequent glitches, and Dr. Bubby (MasterGir), who is cranky and acts rude towards Freeman. Freeman and the scientists experiment on a crystal of unknown origin, which goes awry and triggers a resonance cascade. Freeman, the scientists, and Benry, collectively called "the science team", make their way through the damaged facility while fighting alien creatures and members of the US military, including an obstinate Marine named Forzen (Socpens). During the journey, Coomer accidentally noclips out of the map, causing him to suspect he may be in a video game. Freeman is betrayed by Bubby and Benry, leading him to be captured by the government soldiers deployed to clean up the incident. The soldiers cut off his arm and throw him into a trash compactor. A delirious Freeman comes to and makes his way to an abandoned section of Black Mesa where he rejoins Tommy. He then encounters Coomer, who attempts to use Freeman as a way to escape the video game using several clones of himself.
=== Risk to the social safety net === CBO estimates OBBBA would cause 10.9 million Americans to lose health insurance coverage. Other estimates of this figure said it would strip nearly nine million people of their coverage, leaving between 10.3 million to 14 million people uninsured. The bill's cuts to Medicaid were the largest in the program's history and put rural hospitals at risk of closure with one clinic attributing their announced closure to the bill. The loss of coverage for millions of Americans is expected to strain the finances of hospitals, nursing homes, and community health centers, which will be left to absorb more of the cost of treating the uninsured. Further CBO analysis released August 11, 2025, estimated that the highest 10% of earners would see incomes rise by 2.7% by 2034 mainly due to tax cuts, while the lowest 10% would see incomes fall by 3.1% mainly due to cuts to programs such as Medicaid and food aid. Analysis of the bill by the CBO and multiple think tanks found it to be one of the most regressive bills in decades. The Center for a Responsible Federal Budget estimates that the bill will accelerate the estimated insolvency of Social Security and Medicare by one year. Experts have argued that the bill would create the largest upward transfer of wealth from the poor to the rich in American history due to large-scale benefit cuts paired with tax breaks for high-income earners and corporations.
==== US Federal Trade Commission ==== On 27 February 2019, the United States Federal Trade Commission (FTC) reached a consent decree with ByteDance, fining it US$5.7 million for collecting information from minors under the age of 13 in violation of the Children's Online Privacy Protection Act (COPPA). ByteDance responded by adding a kids-only mode to TikTok which blocks the upload of videos, the building of user profiles, direct messaging, and commenting on others' videos, while still allowing the viewing and recording of content. In May 2020, an advocacy group filed a complaint with the FTC saying that TikTok had violated the terms of the February 2019 consent decree with the FTC, which sparked subsequent congressional calls for a renewed FTC investigation. In March 2022, following a class action lawsuit for violations of COPPA, TikTok settled for US$1.1 million. In March 2024, it was reported that the FTC continues to investigate TikTok. In August 2024, the FTC and US Department of Justice filed a joint lawsuit alleging violations of the 2019 consent decree. In August 2026, TikTok and ByteDance agreed to pay $400 million to settle the lawsuit.
Shulman proposed that lipid-induced insulin resistance results from the accumulation of sn-1,2-diacylglycerol (DAG) in the plasma membrane, which activates novel protein kinase C (nPKC) isoforms—PKCθ in skeletal muscle and PKCε in liver and white adipose tissue—impairing insulin signaling. Shulman's lab explored interventions such as weight loss, thiazolidinediones, adiponectin, leptin, and liver-targeted mitochondrial protonophores to reverse insulin resistance by lowering plasma membrane DAG and inhibiting the nPKC pathway. He also pioneered 13C and 31P NMR methods to measure ATP synthesis and mitochondrial oxidation in vivo. His team identified age-related declines in mitochondrial fat oxidation linked to insulin resistance in elderly individuals, and in insulin-resistant offspring of people with T2D. They showed that chronic AMPK activation drives mitochondrial biogenesis via increased expression of PGC-1α. Shulman used 13C NMR to quantify rates of hepatic glycogenolysis and gluconeogenesis, showing that the latter accounts for over half of fasting hepatic glucose production following an overnight fast overturning the Cahill hypothesis that hepatic glycogenolysis accounts for >90% of glucose production in humans following an overnight fast.
February 6: Law modifying the rules for legal separation. July 15: Law on free medical assistance for people without means: women giving birth are considered equivalent to sick persons. August 19: A law concerning fire safety measures in certain regions of France holds the husband civilly liable for offenses and violations committed by his wife. July 20, 1895: Law on savings banks. December 7, 1897: Law granting women the right to be witnesses in civil status acts and in official documents in general. 1898
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.